Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma
Background: Lung adenocarcinoma (LUAD) is the most common histologic type of non-small cell lung cancer (NSCLC; approximately 60%), and platinum-based chemotherapy is the cornerstone of the treatment for patients with LUAD. However, a considerable number of patients experience tumor recurrence after...
Saved in:
Main Authors: | Rui Li (Author), Junfang Liu (Author), Zekui Fang (Author), Zhenyu Liang (Author), Xin Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment
by: Yao Y, et al.
Published: (2021) -
Bioinformatics Identification of Key Genes for the Development and Prognosis of Lung Adenocarcinoma
by: Xuan Luo PhD, et al.
Published: (2022) -
Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway
by: Wu T, et al.
Published: (2015) -
Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
by: Yuchun Niu, et al.
Published: (2020) -
Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas
by: Mark Menor, et al.
Published: (2019)